Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Loconsole

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The British Journal of Dermatology|May 8, 2013
Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational studyM Esposito, P Gisondi, N Cassano, et al.
Acta Dermato-Venereologica|August 15, 2001
Role of Th2 cytokines, RANTES and eotaxin in AIDS-associated eosinophilic folliculitisP Amerio, R Verdolini, G Proietto, et al.
The Journal of Dermatological Treatment|February 10, 2025
Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinicsE Mortato, F Artosi, C Borselli, et al.
International Journal of Immunopathology and Pharmacology|October 15, 2010
Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study GroupN Cassano, F Loconsole, A Miracapillo, et al.
European Review for Medical and Pharmacological Sciences|December 11, 2014
Investigating psoriasis awareness among patients in Italy: validation of a questionnaireF Bardazzi, P Amerio, G Amoruso, et al.
Journal of Biological Regulators and Homeostatic Agents|November 28, 2008
Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE dataN Cassano, A Galluccio, C De Simone, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 11, 2020
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experienceM C Fargnoli, M Esposito, P Dapavo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 30, 2024
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis)L Gargiulo, L Ibba, P Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 23, 2023
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)L Gargiulo, L Ibba, P Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2020
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in ItalyM Talamonti, M Galluzzo, A Chiricozzi, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The British Journal of Dermatology|May 8, 2013
Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational studyM Esposito, P Gisondi, N Cassano, et al.
Acta Dermato-Venereologica|August 15, 2001
Role of Th2 cytokines, RANTES and eotaxin in AIDS-associated eosinophilic folliculitisP Amerio, R Verdolini, G Proietto, et al.
The Journal of Dermatological Treatment|February 10, 2025
Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinicsE Mortato, F Artosi, C Borselli, et al.
International Journal of Immunopathology and Pharmacology|October 15, 2010
Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study GroupN Cassano, F Loconsole, A Miracapillo, et al.
European Review for Medical and Pharmacological Sciences|December 11, 2014
Investigating psoriasis awareness among patients in Italy: validation of a questionnaireF Bardazzi, P Amerio, G Amoruso, et al.
Journal of Biological Regulators and Homeostatic Agents|November 28, 2008
Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE dataN Cassano, A Galluccio, C De Simone, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 11, 2020
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experienceM C Fargnoli, M Esposito, P Dapavo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 30, 2024
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis)L Gargiulo, L Ibba, P Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 23, 2023
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)L Gargiulo, L Ibba, P Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2020
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in ItalyM Talamonti, M Galluzzo, A Chiricozzi, et al.
Pageof 4